Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics develops targeted immunotherapies that attack solid tumors and aim to enhance the immune system's ability to combat cancer. The company is involved in clinical trials for its neural stem cells engineered to carry an oncolytic virus for treating recurrent high-grade glioma.

Calidi Biotherapeutics

Calidi Biotherapeutics | 2,536 followers on LinkedIn. Calidi Biotherapeutics is a clinical-stage biopharmaceutical company | Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

Quality Assurance Leader in Biotech/Pharma

Violet M. Carvalho

Chief Financial Officer

Andrew Jackson

Cofounder and Vice Chairman of Board of Directors Calidi Biotherapeutics

Scott Leftwich

Chief Business and Revenue Officer | Global

Steve Thesing

👏 Calidi Biotherapeutics recognizes Wendy Pizarro, Esq. , our Chief Legal Officer and Chief Diversity Officer, as a speaker today, October 21, 2024, at the San Diego Precision in Clinical Trials Summit in San Diego, CA. Sherri Monroe She will be speaking on Diversity, Equity and Inclusion Strategies in Clinical Trials and Patient Recruitment. Please reach out to her if you will be attending! #calidi #clinicaltrials #PCTSUMMIT #DEI #endcancer $CLDI

Calidi Biotherapeutics ' Chief Business Officer, Steve Thesing , recently interviewed with Dave Gentry , CEO of RedChip Companies , discussing Calidi's cancer therapies and their place in the future of oncology. Click below for the full interview: #calidi #oncology #virotherapy #endcancer $CLDI

Congratulations to Calidi Biotherapeutics ' Chief Legal Officer and Chief Diversity Officer, Wendy Pizarro, Esq. , for being awarded as a "2024 DEIA Visionary" by the L.A. Times B2B Publishing for her advocacy on health equity in innovative clinical trials. Read more here: https://lnkd.in/gd5v6aVf #DEI #healthequity #deia #indigenouspeoplesday

Calidi Biotherapeutics is thrilled to announce FDA Clearance of the Northwestern University IND Application for Calidi's NeuroNova (CLD-101) Clinical Trial in Newly Diagnosed High-Grade Glioma. Congratulations to the NWU and Calidi teams! Read more below: #calidi #IND #clinicaltrial #virotherapy #neuronova $CLDI #glioblastoma #highgradeglioma #braincancer

Missed Our Virtual Presentation? Watch the Replay Now! Yesterday, we at Calidi Biotherapeutics hosted an exciting virtual presentation diving deep into the groundbreaking science and innovative technology we’re developing to combat cancer. If you missed it, don’t worry! You can catch the full replay and discover how our pioneering approaches are transforming the future of cancer treatment. Watch the Replay Here: https://lnkd.in/gnGR7Fmf Join us on this journey towards a world free from the threat of cancer. Your support and curiosity drive our mission forward! #CalidiBio #CancerResearch #Biotechnology #Innovation #Science #Healthcare

Join Us for an Exciting Webinar: Calidi’s Groundbreaking Cancer Treatment 📅 Date: September 11th 🕓 Time: 4:15 PM ET Discover the future of cancer treatment with Calidi! Our developmental drug targets and destroys cancer cells throughout the body while leaving healthy cells unharmed. Don’t miss this opportunity to learn more about this revolutionary therapy. 🔗 Register now: #calidi #virotherapy #endcancer $CLDI

Calidi Biotherapeutics was recently featured in an article by Fred Grier with the San Diego Business Journal , highlighting the launch of our new subsidiary, Nova Cell. Read more below! #calidi #novacell #stemcells #biotech #sandiego $CLDI

📣 Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results. Read more below! #calidi #virotherapy #stemcells #biotech $CLDI

Calidi Biotherapeutics is proud to announce the launch of our new subsidiary, Nova Cell, and a $3 million aggregate investment from Dr. Ronald Rigor. Dr. Rigor, an accomplished Board-Certified Dermatologist, Internal Medicine, and Stem Cell Therapy expert has taken a significant step to advance regenerative medicine by investing in Nova Cell. “As the founder of one of the largest and fastest growing stem cell centers in the Philippines, I am delighted to partner with and invest in Nova Cell. This is a fantastic opportunity to provide best-in-class stem cell therapy treatments which could meet a huge unmet need in the Philippines. We look forward to bringing Nova Cell’s extensive experience in stem cell therapy production to provide innovative therapies to patients and to elevate the health and wellness industry in the Philippines.” - Dr. Rigor Read more below: #stemcell #calidi #NovaCell $CLDI

Calidi Biotherapeutics recently announced the issuance of a new U.S. patent covering our novel SuperNova technology! “This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone, as we prepare to advance CLD-201 into the clinic." - Allan Camaisa, CEO and Chairman. Read more below: #calidi #patent #SuperNova #virotherapy #stemcells $CLDI

	Dec '21	Dec '22	Dec '23
net income	3.39M -	-25.43M 850.78%	-29.22M 14.90%
depreciation and amortization	153K -	260K 69.93%	1.26M 383.08%
deferred income tax
stock based compensation	1.33M -	6.14M 362.92%	4.81M 21.72%
change in working capital	-290.87K -	3.57M 1,327.02%	-6.24M 274.89%
accounts receivables		-870 -
inventory
accounts payables	63.84K -	1.62M 2,443.90%	-6.17M 479.93%
other working capital	-354.71K -	1.95M 648.34%	-72K 103.70%
other non cash items	-4.24M -	7.28M 271.61%	15.90M 118.39%
net cash provided by operating activities	-1.08M -	-13.21M 1,120.25%	-26.98M 104.20%
investments in property plant and equipment	-206K -	-428K 107.77%	-585K 36.68%
acquisitions net			9K -
purchases of investments	-230M -
sales maturities of investments		190.01M -
other investing activites	-9K -	-66K 633.33%	107K 262.12%
net cash used for investing activites	-230M -	-494K 99.79%	-478K 3.24%
debt repayment	-1.75M -	-1.38M 21.09%	-899K 34.90%
common stock issued	232.79M -	10.76M 95.38%	30.30M 181.50%
common stock repurchased
dividends paid
other financing activites	-640.13K -	10.59M 1,754.67%	604K 94.30%
net cash used provided by financing activities	232.15M -	12.09M 94.79%	29.04M 140.29%
effect of forex changes on cash	-4K -	-26K 550%	-6K 76.92%
net change in cash	642.65K -	-590.65K 191.91%	1.58M 366.99%
cash at beginning of period	420K -	1.06M 153.01%	472K 55.58%
cash at end of period	1.06M -	472K 55.58%	2.05M 334.11%
operating cash flow	-1.08M -	-13.21M 1,120.25%	-26.98M 104.20%
capital expenditure	-206K -	-428K 107.77%	-585K 36.68%
free cash flow	-1.29M -	-13.64M 958.43%	-27.57M 102.08%

COM:CALIDIBIO

Calidi Biotherapeutics

Last Close

2.15

22/11 21:00

Market Cap

37.48M

Beta: -

Volume Today

1.48M

Avg: -

Preview